Free Float 58,69 %
Shares Float 65,6 M
Shares Outstanding 111,77 M
ONCIMMUNE HLDNGS Share · GB00BYQ94H38 · A2AKAW (XLON) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of ONCIMMUNE HLDNGS
No Price
Share Float & Liquidity
Company Profile for ONCIMMUNE HLDNGS Share
Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.
Company Data
Name ONCIMMUNE HLDNGS
Company Oncimmune Holdings plc
Website
https://www.oncimmune.com
Primary Exchange 
London
London
WKN A2AKAW
ISIN GB00BYQ94H38
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Martin John Gouldstone
Country United Kingdom
Currency GBP
Employees 0,0 T
Address MediCity, NG90 6BH Nottingham
IPO Date 2016-05-18
Ticker Symbols
| Name | Symbol |
|---|---|
| Frankfurt | OCY.F |
| London | ONC.L |
More Shares
Investors who hold ONCIMMUNE HLDNGS also have the following shares in their portfolio:
